Conclusion
MISCARRIAGE
The results demonstrate that embryo selection with PGT‑A is not suitable for routine applications in view of the CLBR and the high costs of genetic testing from the theoretical frameworks in health economics in China, it also appears that PGT-A is an expensive way to reduce miscarriage without increasing the chance of achieving a live birth. Our study provides a reference for the government and policy makers to support the future inclusion of IVF treatment in health insurance payments.